One of the first actions by GSK's recently appointed chief scientific officer, Tony Wood, has been to expand a partnership with Tempus aimed at improving the big pharma's R&D productivity ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.